nChroma Bio stopped its only clinical study early and laid off 50% of staff, according to the report. The company formed after the merger of two Boston-area genetic medicine startups that aimed to survive a down market for genetic medicine companies. The decision underscores the fragility of smaller clinical-stage platforms that remain dependent on continued capital and enrollment momentum. While the report does not detail the study outcome in this excerpt, the operational consequence—early study discontinuation—signals a pause in near-term clinical validation. For sector watchers, it’s another example of how the funding cycle for genetic medicine has tightened, forcing companies to reallocate resources and reassess timelines.